Skip to main content

Table 2 The association between XRCC1 Arg194Trp and Arg399Gln polymorphisms and objective response, OS and PFS

From: Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement

XRCC1

Objective response

Overall survival

Progression-free survival

Studies(refs.)

Pooled OR

Ph /I 2(%)

Studies(refs.)

Pooled HR

Ph /I 2(%)

Studies(refs.)

Pooled HR

Ph /I 2(%)

Arg194Trp

 ArgArg vs. TrpTrp

  All

7 [13–16, 23, 26, 27]

0.64(0.44-0.91)

0.19/31.1

3 [23, 26, 31]

1.19(0.73–1.65)

0.92/0.0

3 [23, 26, 31]

1.28(0.74–1.82)

0.92/0.0

  Sample size>100

6 [13–16, 23, 26]

0.67(0.46-0.97)

0.17/35.4

3 [23, 26, 31]

1.19(0.73–1.65)

0.92/0.0

3 [23, 26, 31]

1.28(0.74–1.82)

0.92/0.0

  Year ≥ 2009

5 [13, 14, 23, 26, 27]

0.65(0.44-0.99)

0.09/49.8

3 [23, 26, 31]

1.19(0.73–1.65)

0.92/0.0

3 [23, 26, 31]

1.28(0.74–1.82)

0.92/0.0

 TrpArg vs. TrpTrp

  All

7 [13–16, 23, 26, 27]

1.05(0.73–1.51)

0.35/10.8

-

-

-

-

-

-

  Sample size>100

6 [13–16, 23, 26]

1.04(0.71–1.52)

0.24/25.4

-

-

-

-

-

-

  Year ≥ 2009

5 [13, 14, 23, 26, 27]

0.91(0.60–1.39)

0.56/0.0

-

-

-

-

-

-

 ArgArg + TrpArg vs. TrpTrp

  All

7 [13–16, 23, 26, 27]

0.79(0.56–1.11)

0.32/13.9

1 [26]

-

-

1 [26]

-

-

  Sample size>100

6 [13–16, 23, 26]

0.80(0.57–1.14)

0.23/27.1

1 ([26])

-

-

1 [26]

-

-

  Year ≥ 2009

5 [13, 14, 23, 26, 27]

0.75(0.51–1.10)

0.26/24.6

1 ([26])

-

-

1 [26]

-

-

 ArgArg vs. TrpArg + TrpTrp

  All

7 [13–16, 23, 26, 27]

0.55(0.36-0.84)

0.01/63.0

3 [23, 26, 31]

1.07(0.79–1.35)

0.79/0.0

3 [23, 26, 31]

0.94(0.72–1.17)

0.648/0.0

  Sample size>100

6 [13–16, 23, 26]

0.60(0.39-0.92)

0.02/62.7

3 [23, 26, 31]

1.07(0.79–1.35)

0.79/0.0

3 [23, 26, 31]

0.94(0.72–1.17)

0.648/0.0

  Year ≥ 2009

5 [13, 14, 23, 26, 27]

0.63(0.37–1.05)

0.02/65.9

3 [23, 26, 31]

1.07(0.79–1.35)

0.79/0.0

3 [23, 26, 31]

0.94(0.72–1.17)

0.648/0.0

Arg399Gln

         

 GlnGln vs. ArgArg

  All

10 [13–15, 17, 20, 22–24, 26, 27]

0.77(0.38–1.57)

0.005/62.0

7 [17, 19, 22–24, 28, 31]

1.15(0.61–1.69)

0.006/66.6

5 [17, 22, 23, 26, 31]

0.72(0.48-0.97)

0.136/42.9

  Sample size>100

8 [13–15, 17, 22–24, 26]

0.77(0.35–1.73)

0.002/69.9

7 [17, 19, 22–24, 28, 31]

1.15(0.61–1.69)

0.006/66.6

5 [17, 22, 23, 26, 31]

0.72(0.48-0.97)

0.136/42.9

  Asian

9 [13–15, 17, 20, 23, 24, 26, 27]

0.75(0.33–1.68)

0.003/66.1

4 [17, 23, 24, 31]

0.86(0.41–1.30)

0.052/61.2

4 [17, 23, 26, 31]

0.67(0.40-0.94)

0.106/51.0

  Caucasian

1 [22]

-

-

3 [19, 22, 28]

2.29(1.25-3.33)

0.423/0.0

1 [22]

-

-

  Year ≥ 2009

9 [13, 14, 17, 22–24, 26, 27]

0.83(0.39–1.77)

0.005/63.5

6 [17, 19, 22–24, 31]

1.06(0.54–1.57)

0.011/66.2

5 [17, 22, 23, 26, 31]

0.72(0.48-0.97)

0.136/42.9

 GlnArg vs. ArgArg

  All

10 [13–15, 17, 20, 22–24, 26, 27]

0.90(0.67–1.21)

0.053/46.2

7 [17, 19, 23–25, 28, 31]

0.93(0.68–1.18)

0.003/69.3

4 [17, 23, 26, 31]

0.96(0.79–1.14)

0.416/0.0

  Sample size>100

8 [13–15, 17, 22–24, 26]

0.89(0.63–1.26)

0.02/57.8

7 [17, 19, 23–25, 28, 31]

0.93(0.68–1.18)

0.003/69.3

4 [17, 23, 26, 31]

0.96(0.79–1.14)

0.416/0.0

  Asian

9 [13–15, 17, 20, 23, 24, 26, 27]

0.90(0.65–1.25)

0.035/51.8

4 [17, 23, 24, 31]

0.91(0.56–1.27)

0.003/78.1

4 [17, 23, 26, 31]

0.96(0.79–1.14)

0.416/0.0

  Caucasian

1 [22]

-

-

3 [19, 25, 28]

1.01(0.51–1.51)

0.057/65.2

-

-

-

  Year ≥ 2009

9 [13, 14, 17, 22–24, 26, 27]

0.97(0.79–1.20)

0.112/38.4

5 [17, 19, 23, 24, 31]

0.97(0.64–1.31)

0.003/74.7

4 [17, 23, 26, 31]

0.96(0.79–1.14)

0.416/0.0

 GlnGln + GlnArg vs. ArgArg

  All

13 [13–15, 17–24, 26, 27]

0.72(0.50–1.04)

0.000/70.9

6 [17, 19, 20, 23, 26, 31]

0.73(0.50–1.05)

0.001/72.5

4 [17, 23, 26, 31]

0.94(0.77–1.10)

0.274/22.8

  Sample size>100

10 [13–15, 17, 19, 21–24, 26]

0.78(0.53–1.16)

0.000/72.5

5 [17, 19, 23, 26, 31]

0.85(0.55–1.15)

0.02/65.9

4 [17, 23, 26, 31]

0.94(0.77–1.10)

0.274/22.8

  Asian

11 [13–15, 17, 18, 20, 21, 23, 24, 26, 27]

0.70(0.46–1.07)

0.000/75.7

5 [17, 20, 23, 26, 31]

0.65(0.43-0.98)

0.003/71.7

4 [17, 23, 26, 31]

0.94(0.77–1.10)

0.274/22.8

  Caucasian

2 [19, 22]

0.82(0.46–1.44)

0.966/0.0

1 [19]

-

-

-

-

-

  Year ≥ 2009

12 [13, 14, 17–24, 26, 27]

0.93(0.65–1.34)

0.004/64.3

6 [17, 19, 20, 23, 26, 31]

0.73(0.50–1.05)

0.001/72.5

4 [17, 23, 26, 31]

0.94(0.77–1.10)

0.274/22.8

 GlnGln vs. GlnArg + ArgArg

  All

12 [13–15, 17, 20, 22–24, 26, 27, 29, 30]

0.85(0.50–1.45)

0.028/49.0

5 [19, 24, 26, 29, 30]

1.19(0.53–1.84)

0.01/68.9

2 [26, 30]

0.94(0.37–1.52)

0.435/0.0

  Sample size>100

9 [13–15, 17, 22–24, 26, 29]

0.78(0.43–1.41)

0.015/58.0

4 [19, 24, 26, 29]

1.44(1.01-1.88)

0.686/0.0

1 [26]

-

-

  Asian

10 [13–15, 17, 20, 23, 24, 26, 27, 29]

0.75(0.41–1.37)

0.023/53.4

3 [24, 26, 29]

1.40(0.96–1.84)

0.999/0.0

1 [26]

-

-

  Caucasian

2 [22, 30]

1.58(0.42–5.98)

0.194/40.6

2 [19, 30]

1.43(−1.05–3.91)

0.058/72.1

1 [30]

-

-

  Year ≥ 2009

11 [13, 14, 17, 20, 22–24, 26, 27, 29, 30]

0.87(0.47–1.62)

0.038/51.0

5 [19, 24, 26, 29, 30]

1.19(0.53–1.84)

0.01/68.9

2 [26, 30]

0.94(0.37–1.52)

0.435/0.0

  1. Footnote: OR odds ratio, HR hazard ratio, refs references, OR/HR with the corresponding 95% CIs >/<1 means significance